These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 18990021

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Age-based programs for vaccination against HPV.
    Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E.
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 Nov 01; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.
    Kawai K, de Araujo GT, Fonseca M, Pillsbury M, Singhal PK.
    BMC Infect Dis; 2012 Oct 09; 12():250. PubMed ID: 23046886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N.
    Vaccine; 2014 May 07; 32(22):2645-56. PubMed ID: 24662710
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 16. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A, Ovcinnikova O, Palmer C, Engelbrecht K, Reuschenbach M, Daniels V.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2437703. PubMed ID: 39365579
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.